OPNT News and Press, Opiant Pharmaceuticals Inc. From 08/06/20

SANTA MONICA, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three months ended June ...

SANTA MONICA, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced it will report its second quarter 2020 financial ...

Gainers:  Chesapeake Energy (NYSE: CHK )  +140% . More news on: Chesapeake Energy Corporation, Valaris plc, RigNet, Inc., Stocks on the move, , Read more ...

Opiant Pharmaceuticals (NASDAQ: OPNT )  -32%  after Teva prevails in Narcan patent dispute . More news on: Opiant Pharmaceuticals, Inc., Ascena Retail Group, Inc., Ekso Bionics Holdings, Inc., Stocks on the move, , Read more ...

SANTA MONICA, Calif., June 05, 2020 (GLOBE NEWSWIRE) -- Today, the U.S. District Court for the District of New Jersey entered a decision in the patent litigation regarding NARCAN® (naloxone HCl) Nasal Spray 4mg/spray product. The Court ruled in favor of the Defendants, Teva Pharmaceuti...

SANTA MONICA, Calif., May 26, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, announced today that its Chief Executive Officer, Dr. Roger Crystal, wi...

SANTA MONICA, Calif., May 21, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, announced today that it is changing the format of its 2020 annual ...

Opiant Pharmaceuticals, Inc. (OPNT) Q1 2020 Earnings Conference Call May 12, 2020 4:30 PM ET Company Participants Ben Atkins – Vice President of Communication and Investor Relations Roger Crystal – President and Chief Executive Officer David O’Toole – ...

Opiant Pharmaceuticals (NASDAQ: OPNT ): Q1 GAAP EPS of -$0.40 misses by $0.21 . Revenue of $4.28M (-21.3% Y/Y) misses by $0.57M . Press Release More news on: Opiant Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, ,

SANTA MONICA, Calif., May 12, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three months ended March ...